Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 8/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16625573 | 0.93 | CTSL (0.47) | MAOBCYP3A4PTPN1ABCG2ABCB1 | |
| SCHEMBL16625576 | 0.92 | MAPT (0.51) | MAOBCYP3A4ABCG2ABCB1MAPT | |
| SCHEMBL16625574 | 0.91 | ABCG2 (0.49) | TNFRSF1AABCG2ABCB1MAPTNPC1 | |
| SCHEMBL16616491 | 0.89 | MAOB (0.55) | MAOBCYP3A4TNFRSF1AABCG2ABCB1 | |
| SCHEMBL16616490 | 0.89 | MAOB (0.55) | MAOBCYP3A4TNFRSF1AABCG2ABCB1 | |
| SCHEMBL16625545 | 0.89 | MAOB (0.48) | MAOBCYP3A4TNFRSF1APTPN1ABCG2 | |
| SCHEMBL16625552 | 0.89 | ABCB1 (0.48) | TNFRSF1AABCG2ABCB1 | |
| SCHEMBL16625572 | 0.88 | ABCG2 (0.42) | CYP3A4PTPN1ABCG2ABCB1MAPT | |
| SCHEMBL16616864 | 0.86 | ALDH1A1 (0.57) | MAOBCYP3A4TNFRSF1AABCG2ABCB1 | |
| SCHEMBL16616863 | 0.86 | ALDH1A1 (0.57) | MAOBCYP3A4TNFRSF1AABCG2ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006451-B1 | 2-anilinonicotinyl based chalcones useful as potential anticancer agents and process for preparation thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-04-14 | — | — | US | disclosed |
| US-20150099888-A1 | 2-Anilinonicotinyl Based Chalcones Useful As Potential Anticancer Agents and Process for Preparation Thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099888-A1 | 2-Anilinonicotinyl Based Chalcones Useful As Potential Anticancer Agents and Process for Preparation Thereof | HCCS, WEE2, WEE1 | MAOB 2125/4885CYP3A4 930/4885TNFRSF1A 1747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.